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Objective: Assess the need for folate testing, frequency of corrective action, and determine reference level
for serum folate.
Methods: Serum folate levels in 5313 samples from 4448 patients, and clinical data were reviewed for
patient characteristics and for (a) evidence of corrective action in patients with serum folate values
o5.5 ng/mL, and (b) differences in patients with serum folate levels o5.5 ng/mL and patients with
levels 425.7 ng/mL.
Results: The prevalence of serum folate levels, in patients, o3.0, o4.0, o5.5, o7.0 and o13.0 ng/mL
was 0.58%, 1.55%, 4.9%, 9.98% and 43.21% respectively. Patients with serum folate levels o5.5 ng/mL had
lower serum albumin and hemoglobin. In 64% of patients with serum folate 425.7 ng/mL the sample
was collected after supplementation with folic acid. Of the 128 patients with serum folate o5.5 ng/mL
documentation of supplementation was present in only 38.9%.
Conclusions: Serum folate levels are below the current “normal” level of 3.0 ng/mL in a larger proportion
of tertiary care patients than that reported for ambulatory patients. In patients with folate deﬁciency,
corrective action is lacking in 460% of the patients. Since serum folate levels Z13.0 ng/mL are needed
for optimal prevention of neural tube defects in the embryo/fetus, we propose that normal serum folate
level should be designated to be Z13.0 ng/mL.
& 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Malnutrition is present widely, even in the US and other afﬂuent countries, when one considers both over-nutrition, i.e. obesity, and
under-nutrition of essential nutrients, such as vitamins and minerals, with deﬁciency of vitamin D being perhaps the commonest [1–5].
Folate, also called vitamin B9, (called vitamin B11 in some countries) is one of the essential vitamins and is needed for optimal
hematopoiesis, neurologic functions and embryonic development of the central nervous system. Along with vitamin B12, it is instrumental
in metabolic reactions for synthesis of methionine and nucleic acids [6–8]. Epidemiological studies have documented the role of folate in
preventing neural tube defects and this ﬁnding was the impetus for supplementing some food stuffs and ﬂour with folic acid, in the USA,
starting in 1998. Since the start of supplementation of food stuffs with folic acid, the prevalence of folate deﬁciency has dropped to o1% in
pregnant women [2,3]. However, with greater recognition of the role of folate in various physiological processes there has been suggestion
that folate sufﬁciency needs to redeﬁned [7,9–11].
There is considerable variation in normal or reference value of serum folate, as presented in the literature [6,7,9–14]. In the case of
folate it is only the lower limits of folate concentration that is relevant as there are no known ill-effects from high levels of folate and a
state of folate hyper-vitaminosis has not been documented. The only potential risk of folate supplementation being that neurologic
damage due to concurrent vitamin B12 deﬁciency may be exacerbated. Depending on the source of information the lower limit of normal
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serum folate value ranges from 2.0 to 7.0 ng/mL [1 ng/mL¼2.266 nmol/L] [4,7–19]. Generally levels below 3.0 ng/mL are considered a state
of deﬁciency and levels below 4.0 ng/mL are considered insufﬁcient. These levels are based, in part, on the NHANES data [13]. Serum folate
levels of 3.0 ng/mL or greater are sufﬁcient for avoiding megaloblastic anemia. Hyperhomocysteinemia is prevented with serum folate
level of Z4.0 ng/mL, thus accounting for some sources using a level of 4.0 ng/mL or greater as normal [7,13,16,17]. However, even using
the prevention of elevated serum level of homocysteine may require a serum folate level of about 7.0 ng/mL for an optimal effect [18–20].
Many hospitals and a large reference laboratory use serum folate levels of o3.4 ng/mL as indicative of deﬁciency and o5.5 ng/mL as
evidence of folate insufﬁciency [21].
It is noteworthy that supplementation of food stuffs was instituted for the prevention of neural tube defects (NTD) in the embryo/fetus.
Studies revealed that red cell folate levels of 4906 and 41292 nmol/L were needed to obtain optimal beneﬁt of NTD prevention
[9–11,22–24]. The consensus, optimum red cell folate level has been designated to be 1000 nmol/L. This blood level of folate has been
translated to 7.0 ng/mL by some [10]. However, a more liberal interpretation of red cell folate level of 1000 nmol/L leads us to translate it to
serum folate level of 13.0/mL, according to the following calculation from the data in WHO literature: Normal serum and red cell folate
levels were listed as 10 and 340 nmol/L [14]. Converting red cell folate level of 1000 nmol/L, gives 29.41 nmol/L for serum folate.
Converting nmol/L to ng/mL after dividing 29.41 by 2.2666 yields 12.97 ng/mL. At the two medical centers where the study reported here
was carried out, serum folate levels of o3.4 ng/ml were reported as deﬁcient and o5.5 ng/mL were considered to be insufﬁcient.
Thiesen-Toupal et al. examined serum folate levels in outpatient setting and found that fewer than 0.06% of the samples had levels
o3.0 ng/mL and about 0.26% with levels o4.0 ng/mL. The authors attributed the low prevalence of folate deﬁciency to the routine
supplementation of food stuffs with folic acid. They recommended discontinuation of routine testing for serum folate with the caution
that the results may not be generalizable to other institutions or populations [25]. This report prompted us to look at the data at two
tertiary care hospitals.
2. Methods
The study was conducted at two medical school afﬁliated, tertiary care medical centers, one each in Missouri and Georgia. Both
hospitals have about 500 beds each and serve as the safety net hospitals for the local population. Both hospitals are also level 1 trauma
centers. The laboratories at both medical centers are accredited by the College of American Pathologists and performed the testing using
Beckman analyzers and chemiluminescence methodology.
All of the tests done in one year, July 2013 through June 2014, at both medical centers, were analyzed for prevalence of various serum
levels of folate in all samples and patients. All patients on whom serum folate level testing was done were included. In case of multiple
results for a given patient, only the lowest value was retained. Patients below the age of 18 years were excluded from further analysis.
For the patients at the Georgia medical center, the clinical parameters for the 128 patients with serum folate values below 5.5 ng/mL and
an equal number of patients with highest serum folate levels, 425.7 ng/mL, were retrieved through chart review. Relevant clinical
parameters between the two groups were compared by using Student's t test for continuous variables and Chi-square test for discrete
variables. To ascertain the potential effect of location of the home address as a surrogate for economic status, zip codes for the high and
low folate groups were compared. Only the zip codes with at least ﬁve members of either group were included and the data was analyzed
by goodness of ﬁt analysis. The p values were corrected for the number of comparisons, i.e., Bonferroni correction was applied.
The chart review was geared toward identifying risk factors for low serum folate, documentation of corrective action in patients found
to have low levels, and clinical circumstances resulting in low and high serum folate levels. Other data collected were age, sex, race, bmi,
hemoglobin, mean red cell corpuscular volume (MCV), and serum levels of creatinine, albumin, alanine aminotransferase (ALT), iron,
ferritin, and B12. The gender distribution was nearly identical in the two groups and was not included in the statistical analysis.
To gain an understanding of the relation between serum and red blood cell folate levels, all instances of folate analysis for years 2007–
2013 at the Georgia medical center were examined. In cases where serum and red cell folate levels were analyzed within 2 days of each
other, the results from the two sources were compared. Reporting format for serum folate levels changed over the years. Before 2013,
the highest value reported was 20.0 ng/mL and in samples with value reported as 420.0 ng/mL, the samples were arbitrarily assigned a
value of 25.0 ng/mL. The serum folate equivalent of red cell folate level of 1000 nmol/L was estimated by interpolation.
IRB approval: This study was approved by the Institutional Review Boards at Georgia Regents University, Augusta, GA and University of
Missouri-Kansas City and Truman Medical Center, Kansas City, MO.
3. Results
3.1. Prevalence of deﬁciency
The prevalence of serum folate levels in the combined sample pool, and patients, from the two medical centers is shown in Tables 1
and 2. The proportion of samples, at the two medical centers, with serum folate levels below 3.0, 3.4, 4.0, 5.5, 7.0 and 13.0 ng/mL was,
0.51%, 0.73%, 1.41%, 4.76%, 9.52%, and 40.82% respectively. The prevalence of given serum folate levels in individual patients is given in
Table 2. The proportion of patients, at the two medical centers, with serum folate levels below 3.0, 3.4, 4.0, 5.5, 7.0 and 13.0 ng/mL was,
0.58%, 0.85%, 1.55%, 4.90%, 9.98%, and 43.21% respectively.
3.2. Documentation of replacement therapy
Medical records were examined for follow-up action in patients found to have low serum folate levels. In the 36 patients with serum
folate levels o3.4 ng/mL, 16 (55.6%) had documentation of replacement. Replacement treatment was not standardized and included
1.0 mg of folic acid or multivitamin tablet without details of the composition of the multivitamin preparations. Of the total 226 patients
with serum folate levels o5.5 ng/mL, 88 (38.9%) had documentation of replacement treatment (Table 3).
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3.3. Comparison of demographic and health data between groups of patients with serum folate o5.5 ng/mL and those with levels 425.7 ng/mL
The comparative data for the two groups are given in Table 4A and B, are from the Georgia medical center. Men and women were
present in nearly equal numbers in the two groups and this data was not included in the statistical analysis. There were more white
patients in the group with serum folate levels 425.7 ng/ml (N¼78) than in the group with folate levels o5.5 ng/mL (N¼52).
The difference was statistically signiﬁcant by itself, but p value was 40.05 after Bonferrone correction.
There were no signiﬁcant differences between the two groups (o5.5 ng/mL and 425.7 ng/mL) in the values for bmi, ALT, iron, B12 and
prevalence of documented excessive use of alcohol. Before Bonferrone corrections the following parameters were different between the
groups at p value o0.05: Age and MCV were higher in the 425.7 ng/mL group; creatinine and ferritin were higher in the o5.5 ng/mL
group; more patients in the o5.5 ng/mL group were judged to be at risk for malnutrition. After correcting the p value for the 14
comparisons, none of these parameters were signiﬁcantly different between the two groups. ALT levels were signiﬁcantly lower in the
group with serum folate levels of o3.4 ng/mL (Table 5).
The two groups were different both statistically as wells as in a clinically meaningful way for hemoglobin, albumin and documentation
of folate supplementation before collection of sample. The o5.5 ng/mL group had lower hemoglobin (10.5 gm/dL vs. 12.02 gm/dL),
and albumin (3.48 gm/dL vs. 3.96 gm/dL) as compared to the group with serum folate 425.7 ng/mL. None of the patients in o5.5 ng/mL
group had documentation of folate supplementation before collection of sample for testing. In the 425.7 ng/mL group 82 of 128 patients
had documented administration of folate supplement as folic acid or multivitamin preparation, before sample collection. In an additional
33 patient, the subject had been at another healthcare facility immediately prior to transfer to the Georgia Medical Center or had spent a
day in emergency department or another patient care unit, prior to sample collection, though documentation of folic acid administration
was lacking. This difference was statistically signiﬁcant as well clinically relevant.
Analysis of the distribution of patients in various zip codes did not reveal any meaningful or statistically signiﬁcant difference among
the patients with low and high serum folate levels (Table 6). The p value of the comparison was 0.86.
Table 1
Distribution of serum folate levels in all samples examined in 2013–2014.
ng/mL Serum samples %
GA MO Total
2696 2617 5313
o3.0 15 12 27 0.51
o3.4 21 18 39 0.73
o4.0 41 34 75 1.41
o5.5 153 100 253 4.76
o7.0 304 202 506 9.52
o13.0 1202 967 2169 40.82
Table 2
Distribution of serum folate levels in the patients examined in 2013–2014.
ng/mL Patients %
GA MO Total
2075 2373 4448
o3.0 14 12 26 0.58
o3.4 20 18 38 0.85
o4.0 36 33 69 1.55
o5.5 128 90 218 4.90
o7.0 260 184 444 9.98
o13.0 1014 908 1922 43.21
Table 3
Documentation of folate supplementation in patients with subnormal folate levels.
Supplementation treatment
ng/mL Number Supplemented %
o3.4 GA 20 10 50.00
MO 16 10 62.50
Total 36 20 55.56
43.4o5.5 GA 108 27 25.00
MO 82 41 50.00
Total 190 68 35.79
Total o5.5 226 88 38.94
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Estimation of serum folate from red cell folate measurements: RBC folate of 1000 nmol/L translated to 9.23 ng/mL of serum folate,
based on the 122 samples that were comparable (Fig. 1). It is worth pointing out that the correlation between serum and red cell folate
levels was, in general, poor.
One item of note was the low ALT levels in the o3.4 ng/mL group (Table 5). Even between the two groups of patients with folate levels
o3.4 ng/mL (N¼20) and those with folate levels 43.4 and o5.5 ng/mL (N¼105), the ALT levels were highly signiﬁcantly lower in the
o3.4 ng/mL group (po0.00000000014). The average value in the o3.4 ng/ml group was 10.45 IU/L and in the 43.4o5.5 ng/ml group it
was 27.72 IU/L. The difference is even more remarkable in that 19 of the 20 patients in the o3.4 ng/mL group had ALT values o10 and
were assigned values of 10 as a default. Only 4 of the 105 patients in the other group had ALT values of o10.
Table 4
A and B Comparison of clinical parameters between the low (o5.5 ng/mL) and high (425.7 ng/mL) serum folate groups. The items indicated in bold were signiﬁcantly
different between the two groups before correction for the number of parameters compared. The items indicated in italics were statistically signiﬁcantly different between
the two groups after Bonferroni correction.
A
Age BMI Hb MCV Creat Alb ALT Iron Ferritin B12
o5.4 ng/mL
Mean 53 28.5 10.5 90.1 2.01 3.48 24.96 57.75 983.15 709.8
SD 14.9 7.85 2.47 10.21 2.55 0.74 21.96 45.05 1619.55 1194.2
Number 128 125 128 128 128 125 125 67 64 128
425.7 ng/mL
Mean 58.38 27.2 12.02 93.23 1.36 3.96 33.9 60.7 406.6 919.7
SD 18.17 7.1 2.44 7.74 1.62 0.57 47.6 48.1 570.5 1690.4
Number 128 128 120 120 120 118 118 41 42 124
Raw p 0.0079 0.14 0.0000032 0.0069 0.017 0.000000079 0.059 0.56 0.012 0.24
Corrected p 0.11 1.97 0.000045 0.096 0.24 0.0000011 0.83 7.91 0.17 3.31
B
Male Race Alcohol At risk Suppl
o5.4 ng/mL
56 W¼52 21 107 0
B¼71
H¼2
O¼3
425.7 ng/mL
54 W¼78 28 91 82(þ33)
B¼46
H¼3
O¼1
Raw p 0.0083 0.27 0.017 0
Corrected p 0.12 3.72 0.24 0
W¼White, B¼African American, H¼Hispanic, O¼other; At risk¼at risk of malnutrition, Suppl¼supplementation with folic acid or multivitamin.
Table 5
ALT values in patients with serum folate o3.4 ng/mL vs. those with folate 43.4 ng/mL and o5.5 ng/mL.
Folate o3.4 ng/mL 43.4o5.5 ng/mL
Number 20 105
Mean 10.45 27.72
SD 2.01 23.03
p Value 0.000000000014
Table 6
Zip codes for the home addresses of the patients with low (o5.5 ng/mL) and high (425.7 ng/mL) serum folate levels were compared. Only the zip codes with at least ﬁve
members of one of the groups were included. The distribution of patients in the various zip codes, and by inference, economic status, were not meaningfully or statistically
different. The data was analyzed for goodness of ﬁt and p value was 0.86.
Zip code Low High
29801 5 3
30809 5 4
30815 6 6
30901 11 8
30904 12 9
30906 13 18
30907 10 5
30909 6 5
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4. Discussion
Optimum, minimum serum level of folate apparently has not been established given the wide variation in the values cited as the lower
limit of normal for serum folate [2,3,9–12,14–22]. If serum folate level of 3.0 ng/ml is accepted as normal then it may well be true that
folate deﬁciency is rare in the US and testing should be discontinued. Other sources cite serum folate levels of o5.5 ng/mL as a state of
insufﬁciency. It has also been stated that serum folate level of 47.0 ng/mL would be optimal for preventing neural tube defects [17].
However, trials measuring red cell folate level and occurrence of neural tube defects reported red cell folate levels of greater than
906 nmol/L and 1000 nmol/L as being optimum for prevention of neural tube defects [9,10,17]. The highest level with the optimum
protection being 1292 nmol/L of red cell folate, however, the authors suggest 1000 nmol/L as optimum [10]. Red cell folate level of
1000 nmol/L translates to about 13.0 ng/mL of serum folate as described previously, however it is not clear if the relation is linear and the
extrapolation may have provided an overestimate of the serum equivalent of the RBC folate. Data of Bruyn et al. suggest that RBC folate of
1000 nmol/L would be equal to about 10.7 ng/mL [26]. Conversion of the red cell folate level of 1000 nmol/L to serum folate level in ng/mL,
using the imperfect data in our patients, in whom both sources were tested, yielded a value of 9.23 ng/mL. Given that serum folate levels
tend to ﬂuctuate rapidly with folate intake status whereas red cell folate levels seem to represent the average value over the life span of
red cells, using the patient data is unlikely to be an ideal way of performing the comparison. Conducting a study analyzing the serum and
red cell folate levels, in healthy subjects, in a steady state intake of folate over four months may be warranted.
If we accept the WHO deﬁnition of health, “Health is a state of complete physical, mental and social well-being and not merely the
absence of disease or inﬁrmity”, then using a serum folate level of 3.0 ng/mL that merely prevents the appearance of megaloblastic
anemia, is at best, improper [27]. Even if normalization of serum homocysteine levels were considered to be a more objective measure of
folate sufﬁciency, the lower limit of normal serum folate levels should be set at about 7.0 ng/mL [18–20]. If we accept that preventing
neural tube defects in the embryo/fetus is a physiologic function of folate, then the minimum serum folate reference level should be
designated to be 13.0 ng/mL. We would support going with this high level given that no ill-effects have been documented with this level,
or higher, and we recommend that optimum minimum normal level of serum folate be pegged at 13.0 ng/mL [9–12]. If the risk of
exacerbating neural damage due to co-existing vitamin B12 deﬁciency is a consideration, as has been suggested, perhaps food
supplementation should be extended to vitamin B12 as well [28,29]. Since folate deﬁciency in men has been suggested to be contributory
to neural tube defects, this reference value should be universal, not just for women of childbearing age [30].
In addition to the well documented risk of neurologic damage due to folic acid supplementation in patients with vitamin B12
deﬁciency, a number of potential toxic effects resulting from high levels of folate have been recognized. Administration of folate or high
serum levels of folate may not be desirable for patients on anti-folate drugs for malaria, rheumatoid arthritis, psoriasis and cancers. Folate
suppresses initiation of carcinogenesis but may also act as a promoter. These and other potential undesirable effects of high intake of folate
are reviewed by Smith et al. [20]. These authors suggest a serum folate level of about 26.0 ng/mL as the safe upper limit.
Based on the patient populations tested in Georgia and Missouri Medical Centers, depending on one's viewpoint about 0.5–43.21% of
the patients were deﬁcient in folate. For this discussion we will treat serum folate levels below 5.5 ng/mL as a state of folate insufﬁciency
and accept that about 5% of the patients seen at tertiary care medical centers are folate insufﬁcient.
The higher than expected prevalence of folate deﬁciency in the population tested is likely due to higher disease burden in the people-
seeking healthcare at a tertiary care medical centers. In reviewing the medical records we determined that 107 of 128 patients with serum
folate o5.5 ng/mL and 91 of 128 patients with high serum folate levels were at risk of malnutrition. The risk factors were similar in the
two groups and consisted of neuropsychiatric disorders, alcohol and illegal substance abuse, dysphagia, altered mental status, dementia,
HIV/AIDS, advanced malignancy, gastric resection and gastric bypass surgery, end stage renal disease and major depressive disorder
[31,32]. In fact, the most striking difference accounting for the high levels of serum folate in the group with levels 425.7 was the
occurrence of folic acid supplementation before collection of specimen for testing. In 82 of the 128 patients with high serum folate levels
there was documentation of folate supplementation with either folic acid or multivitamins. In an additional 33 of the patients with high
serum folate levels, it was likely that they received folate supplementation as medication or hospital food, as these individuals were
transferred from another healthcare facility or were in the medical center during the day before specimen collection. Thus, it is likely that
many, albeit an undetermined number, of the patients with high serum folate levels were folate deﬁcient prior to supplementation.
MCV was higher in the high folate group (93 in the 425.7 ng/mL group vs. 90 in the o5.5 ng/mL group), suggesting that the group was
likely folate deﬁcient in the recent past. In general, patients with serum folate levels o5.5 ng/mL had higher disease burden than patient
0
5
10
15
20
25
30
0 1000 2000 3000 4000 5000 6000
S
er
um
 fo
la
te
 in
 n
g/
m
L
Red cell folate in nmol/L
Fig. 1. Comparison of red cell folate level in nmol/L and serum folate in ng/mL for the patients in whom both samples were tested within two days of each other.
By interpolation, red cell folate of 1000 nmol/L translates to about 9.23 ng/mL of serum folate.
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with high serum folate as revealed by the low hemoglobin and albumin levels in the former group. At least 4.9% of the patients seeking
care at our hospitals had serum folate levels in the insufﬁcient range. It is likely and many of the patients with higher levels had received
folic acid supplementation prior to testing, therefore the prevalence of folate insufﬁciency is higher than the data suggest.
It has been suggested that because the prevalence of folate deﬁciency is so low in the ambulatory persons, testing for serum should be
discontinued. The same approach could also be taken for patients seeking treatment at tertiary care medical centers and all patients could
be administered folic acid supplementation as that may be less expensive than testing. However, we recommend that patients continue to
be tested, as serum folate levels are an indicator of malnutrition. Given that folate stores are depleted in 4–5 months of inadequate intake,
and serum levels of folate decline after only a few days of negative folate balance, low serum folate level may be a leading indicator of
under-nutrition of essential nutrients, obesity in the patient notwithstanding [15,16,31,32].
It was unsettling to discover that only about 39% of the patients with insufﬁciency of folate had documentation of supplementation
with this essential vitamin. This was not an isolated event at our particular medical centers, as earlier studies reported that low serum
levels of folate were acknowledged in only about half of the instances and supplementation was implemented in only a quarter of the
events [15,31,32]. This could be used as an argument that patients should be administered folic acid without testing ﬁrst. However doing
that would miss an easily available marker of under-nutrition of essential nutrients that may require more corrective action than just
administering folic acid [31,32].
This study has the usual shortcomings of a retrospective review, however, since we dealt with the real life situation of practice rather
and the controlled environment of a prospective trial, the ﬁndings are expected to be generalizable.
The ﬁnding of low ALT in patients with serum folate levels of o3.4 ng/mL may be a chance occurrence despite the high statistical
signiﬁcance. It is plausible that low ALT is a marker of deﬁciency of other nutrients, such as pyridoxine that has been associated with low
ALT activity. The issue warrants further investigation.
5. Conclusions
Serum folate levels should be tested, at admission, in tertiary care patients as this analyte serves as a leading indicator of nutritional
deﬁciency. We recommend that normal serum folate level should be recognized to be 13.0 ng/mL.
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Note added in proof
Huo et all demonstrated that combined use of anti-hypertensive medication and 0.8 mg folic acid was more effective in preventing
strokes in hypertensive patients than anti-hypertensive alone. The average serum folate, at the end of the trial was 13.0 ng/mL in the un-
supplemented group and 19.9 ng/mL in the supplemented group [33]. This ﬁnding further supports the concept of establishing serum
folate level of 13.0 ng/mL as the lower limit of normal value.
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